| Literature DB >> 27012484 |
Bruno Dubois1, Harald Hampel2, Howard H Feldman3, Philip Scheltens4, Paul Aisen5, Sandrine Andrieu6, Hovagim Bakardjian7, Habib Benali8, Lars Bertram9, Kaj Blennow10, Karl Broich11, Enrica Cavedo12, Sebastian Crutch13, Jean-François Dartigues14, Charles Duyckaerts15, Stéphane Epelbaum16, Giovanni B Frisoni17, Serge Gauthier18, Remy Genthon19, Alida A Gouw20, Marie-Odile Habert21, David M Holtzman22, Miia Kivipelto23, Simone Lista24, José-Luis Molinuevo25, Sid E O'Bryant26, Gil D Rabinovici27, Christopher Rowe28, Stephen Salloway29, Lon S Schneider30, Reisa Sperling31, Marc Teichmann16, Maria C Carrillo32, Jeffrey Cummings33, Cliff R Jack34.
Abstract
During the past decade, a conceptual shift occurred in the field of Alzheimer's disease (AD) considering the disease as a continuum. Thanks to evolving biomarker research and substantial discoveries, it is now possible to identify the disease even at the preclinical stage before the occurrence of the first clinical symptoms. This preclinical stage of AD has become a major research focus as the field postulates that early intervention may offer the best chance of therapeutic success. To date, very little evidence is established on this "silent" stage of the disease. A clarification is needed about the definitions and lexicon, the limits, the natural history, the markers of progression, and the ethical consequence of detecting the disease at this asymptomatic stage. This article is aimed at addressing all the different issues by providing for each of them an updated review of the literature and evidence, with practical recommendations.Entities:
Keywords: Alzheimer's disease; Amyloid PET; Asymptomatic; Biomarkers; Blood biomarkers; CSF biomarkers; Diagnostic criteria; Genetics; MRI; Pathophysiology; Preclinical; Tau PET
Mesh：
Year: 2016 PMID： 27012484 PMCID： PMC6417794 DOI： 10.1016/j.jalz.2016.02.002
Source DB: PubMed Journal: Alzheimers Dement ISSN： 1552-5260 Impact factor: 21.566